Abiraterone for treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Keyphrases

• Meta-analysis 100%
• Systematic Meta-analysis 100%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 100%
• Abiraterone 100%
• Confidence Interval 62%
• Hazard Ratio 50%
• Overall Survival 37%
• Randomized Controlled Trial 37%
• Risk Ratio 37%
• Placebo 37%
• Radiographic Progression-free Survival 37%
• Free Time 25%
• Adverse Events 25%
• Objective Response Rate 25%
• PSA Response 25%
• Prednisone 25%
• PSA Progression 25%
• Chemotherapy 12%
• Statistical Analysis 12%
• Stata 12%
• Embase 12%
• Web of Science 12%
• Nave 12%
• Prostate Cancer 12%
• Evaluation System 12%
• Cochrane 12%
• Cochrane Library 12%
• PubMed 12%
• Risk of Bias 12%
• Evaluation Assessment 12%
• Assessment Development 12%
• Grading of Recommendations 12%
• Developmental Systems 12%
• Assessment System 12%
• New Standards 12%
• Time to Progression 12%
• Prior Chemotherapy 12%
• Phase II Trial 12%
• Castration 12%
• Science Libraries 12%
• Luteinizing Hormone 12%
• Bilateral Orchiectomy 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Abiraterone 100%
• Castration Resistant Prostate Cancer 100%
• Randomized Controlled Trial 37%
• Overall Survival 37%
• Placebo 37%
• Progression Free Survival 37%
• Adverse Event 25%
• Prednisone 25%
• Chemotherapy 12%
• Prostate Cancer 12%
• Gonadorelin Derivative 12%
• Patient History of Chemotherapy 12%

Agricultural and Biological Sciences

• Meta-Analysis 100%
• Systematic Review 100%
• Abiraterone 100%
• Confidence Interval 62%
• Placebo 37%
• Prednisone 25%
• Spider Web 12%
• Gonadotropin-Releasing Hormone Analogue 12%